Convergence Pharmaceuticals Limited , the company focused on the development of novel and high value analgesic medicines for the treatment of chronic pain, is pleased to announce that its novel sodium channel blocker, CNV1014802 , has been granted orphan-drug designation by the US Food and Drug Administration for the treatment of trigeminal ... (more)
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/Phase+News/Convergence-Pharmaceuticals-Receives-Orphan-Drug-D/ArticleNewsFeed/Article/detail/819149?ref=25
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/Phase+News/Convergence-Pharmaceuticals-Receives-Orphan-Drug-D/ArticleNewsFeed/Article/detail/819149?ref=25
No comments:
Post a Comment